MedTrace Logo

Safety and Efficacy of Dr. Tagliaferri's Menopause Formula

NCT01957306 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-06-13

No results posted yet for this study

Summary

The primary goal of this study is to evaluate the safety and efficacy of 12 weeks of treatment of 4 grams/day of Dr. Tagliaferri's Menopause Formula (administered as 2 grams PO BID) in reducing the frequency of menopausal vasomotor symptoms among healthy, postmenopausal women, aged 40-65, with moderate to severe hot flushes.

Conditions

Interventions

DIETARY_SUPPLEMENT

Dr. Tagliaferri's Menopause Formula

Administered as 2 grams PO BID

Sponsors & Collaborators

  • Herba Buena, Inc

    lead INDUSTRY

Principal Investigators

  • William Koltun, MD · Medical Center for Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957306 on ClinicalTrials.gov